Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Rational Dosage Regimen: Maintenance Dose and Loading Dose01:24

Rational Dosage Regimen: Maintenance Dose and Loading Dose

5.9K
A rational dosage regimen considers a drug's pharmacokinetics, including its absorption, distribution, metabolism, and elimination from the body. By understanding these factors, the appropriate dosage can be determined, and the dosing schedule can be designed to achieve and maintain the desired therapeutic effect while minimizing adverse effects.
In most cases, drugs are administered repetitively or infused continuously to maintain a steady-state concentration in the body. At a steady...
5.9K
Dosage Regimens: Designs and Approaches01:28

Dosage Regimens: Designs and Approaches

566
Designing a dosage regimen, which refers to the manner of drug administration, is a complex process involving the selection of drug dose, route, and frequency. This process is underpinned by pharmacokinetic parameters derived from tests and population averages. These parameters are then tailored to patient-specific variables such as diagnosis, demographics, and allergy status. Once therapy commences, therapeutic response monitoring is critical and achieved through clinical and physical...
566
Determination of Multiple Dosing Parameters: Steady-State, Minimum and Maximum Concentrations01:15

Determination of Multiple Dosing Parameters: Steady-State, Minimum and Maximum Concentrations

355
Gentamicin, an aminoglycoside antibiotic, is commonly administered via intermittent intravenous infusion to treat severe infections. An intermittent one-hour infusion of gentamicin, administered at eight-hour intervals, allows for precise control of plasma drug concentrations, minimizing toxicity while ensuring therapeutic efficacy. Pharmacokinetic principles govern the dynamics of plasma concentrations and can be mathematically described using specific equations.The plasma drug concentration...
355
Determination of Multiple Dosing Parameters: Loading and Maintenance Doses01:25

Determination of Multiple Dosing Parameters: Loading and Maintenance Doses

369
A loading dose is an essential pharmacological strategy to rapidly achieve the target plasma drug concentration necessary for an immediate therapeutic effect. This approach is especially critical for drugs characterized by slow absorption or extended half-lives, where delaying therapeutic plasma levels could compromise treatment outcomes. By administering a loading dose, clinicians ensure a prompt onset of drug action, even for agents with complex pharmacokinetic profiles.Achieving steady-state...
369
Therapeutic Drug Monitoring: Drug Analysis Methods01:26

Therapeutic Drug Monitoring: Drug Analysis Methods

317
Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood or body tissues to tailor drug therapy effectively. This monitoring is critical for managing drugs with narrow therapeutic indices like digoxin and phenytoin, ensuring they are both safe and effective. For instance, monitoring theophylline levels in asthma patients involves precision and sensitivity to adjust doses according to individual responses to therapy, ensuring efficacy and...
317
Methods of Medium Optimization01:28

Methods of Medium Optimization

63
Optimizing growth media enhances microbial proliferation and maximizes product yield. Statistical experimental design methodologies provide structured and reproducible approaches, offering progressively higher levels of robustness and efficiency.The One-Factor-at-a-Time (OFAT) MethodThe One-Factor-at-a-Time (OFAT) method involves adjusting a single variable while keeping all others constant. However, it cannot detect interactions between variables, often leading to suboptimal outcomes when...
63

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Asymmetric Chichibabin diradicaloids: synthesis <i>via</i> oxidation of SOMO-HOMO inversion radicals and near-infrared absorption for electrochromism.

Chemical science·2026
Same author

Metabolomic differences in the Ophiura sarsii complex from the Yellow Sea Cold Water Mass and Bering Sea Cold Pool.

Comparative biochemistry and physiology. Part D, Genomics & proteomics·2026
Same author

Establishment and characterization of an ovarian cell line from red seabream (Pagrus major) and its application in fish toxicology.

In vitro cellular & developmental biology. Animal·2026
Same author

SETD7 depletion enhances white adipose browning and ameliorates metabolic disorders in obese mice.

Cell death and differentiation·2026
Same author

Diagnostic performance of contrast-enhanced ultrasound in distinguishing lymphoma from non-lymphoma lesions in salivary gland: a retrospective study.

Frontiers in oncology·2026
Same author

PRKN Ser131 phosphorylation promotes cigarette smoke-induced mitophagy impairment and epithelial cell senescence via MKK3/p38 MAPK activation: An in vitro and in vivo study.

Tobacco induced diseases·2026

Related Experiment Video

Updated: Apr 13, 2026

High Content Screening in Neurodegenerative Diseases
13:32

High Content Screening in Neurodegenerative Diseases

Published on: January 6, 2012

17.6K

An effective system for senescence modulating drug development using quantitative high-content analysis and

Yajie Hu1, Xueqi Xue1, Tian Han1

  • 1Discovery Biology Unit, WuXi Biology, WuXi AppTec Ltd., Shanghai, China.

Communications Biology
|August 30, 2025
PubMed
Summary

This study introduces a new high-content analysis system for evaluating cellular senescence markers, improving drug development for aging research. The system enables high-throughput screening of senomorphic, senolytic, and seno-inducing agents.

More Related Videos

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
09:41

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

Published on: July 15, 2015

8.7K
SA-&#946;-Galactosidase-Based Screening Assay for the Identification of Senotherapeutic Drugs
07:39

SA-β-Galactosidase-Based Screening Assay for the Identification of Senotherapeutic Drugs

Published on: June 28, 2019

24.2K

Related Experiment Videos

Last Updated: Apr 13, 2026

High Content Screening in Neurodegenerative Diseases
13:32

High Content Screening in Neurodegenerative Diseases

Published on: January 6, 2012

17.6K
An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
09:41

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

Published on: July 15, 2015

8.7K
SA-&#946;-Galactosidase-Based Screening Assay for the Identification of Senotherapeutic Drugs
07:39

SA-β-Galactosidase-Based Screening Assay for the Identification of Senotherapeutic Drugs

Published on: June 28, 2019

24.2K

Area of Science:

  • Biogerontology
  • Drug Discovery
  • Cellular Biology

Background:

  • Cellular senescence is crucial in aging research and anti-senescence drug development.
  • Current senescence-associated beta-galactosidase (SA-β-gal) assays are non-quantitative and labor-intensive.
  • A need exists for efficient, high-throughput methods to evaluate senescence modulators.

Purpose of the Study:

  • To develop and validate a multiplex high-content analysis system for high-throughput screening of senescence modulators.
  • To enable quantitative evaluation of senomorphic, senolytic, and seno-inducing agents.
  • To facilitate drug development for anti-senescence therapies.

Main Methods:

  • Development of a multiplex high-content analysis system.
  • High-throughput screening of senescence modulators on fibroblasts.
  • Determination of IC50 or EC50 values for senescence modulators.

Main Results:

  • The developed system is effective and reproducible for evaluating senescence modulators.
  • The system allows for simultaneous assessment of senomorphic, senolytic, and seno-inducing agents.
  • New molecular entities modulating MMC-induced senescence were identified, suggesting novel cellular targets.

Conclusions:

  • The novel high-content analysis system significantly advances the screening and evaluation of senescence modulators.
  • This platform is essential for accelerating drug development in aging research and anti-senescence therapy.
  • The identification of new molecular entities highlights the system's potential for discovering novel therapeutic targets.